ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure

Key Takeaways Acadia's ACP-101 failed to show benefit in phase III PWS study, ending its development.Nuplazid and Daybue sales rose double digits in H1 2025, fueling ACAD's revenue growth.SLNO stock jumped as Vykat XR gains ground with ACAD exiting the PWS hyperphagia market.Shares of Acadia Pharmaceuticals (ACAD) lost 9.9% on Wednesday after the company announced a disappointing update from a late-stage study of its investigational candidate, intranasal carbetocin (ACP-101), in patients with hyperphagia in ...